Mateos, M., Hungria, V., Beksac, M., Robak, P., Kim, K., Voloshin, S., Sia, H., García, E. G., Martinez, G., Min, C., Lacerda, M. P. D., Balarí, A. S., Špička, I., Delimpasi, S., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hajek, R., Grosicki, S., Zafar, S., Abdallah, A., Mouro, J., Khalaf, Z., Baig, H., Moore, A., Lin, C. P., Nichols, M., Garrobo-Calleja, I., Varghese, S., Pirooz, N., Lee, J., Eccersley, L., Manasanch, E., Pour, L., Dimopoulos, M. (2025). Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis. Blood. https://doi.org/10.1182/blood-2025-5820